Rigdon Lentz received his Bachelors degree at the University
of Tennessee with a major in Biology. He graduated the U.S.
Naval Aviation Officer Candidate School and became a Naval Aviator
and received the "Distinguished Naval Graduate" award.
Dr. Lentz was a Naval Flight Instructor in Pensacola, Florida
where he was elected "Instructor of the Year", and
was the recipient of the Medical Officer Scholarship Award for
medicine. He was graduated cum laude from Georgetown University
Medical School in 1975 and was elected to AOA honor medical
society and received the Mosby Scholarship award.
He completed his internship in General Surgery, residency in
Internal Medicine and fellowship in Hematology/Oncology at the
Naval Medical Center in San Diego.
He was the Chief of Oncology at the Naval Medical Center Long
Beach, California. Dr. Lentz was appointed Assistant Professor
of Medicine at the University of California, San Diego and Associate
Professor of Medicine at the University of California, Irvine.
In addition to maintaining a full time clinical practice in
Hematology and Oncology, Dr. Lentz has served as Chairman, Hematology
Oncology Department Chairman, Tumor Board Chairman, Cancer Committee
Chairman, Tumor Registry, Chairman, Disaster Preparedness Committee,
Member, Executive Committee and Credentials Committee.
He was the Principal investigator of the US Naval Leukopenia
Research Project Phase 1, 2 and 3 studies, clinical and laboratory
He has served as Chairman of major tumor boards, director of
cancer centers, and Principal Investigator of Phase 1 and 2
clinical trials both of drugs and medical devices.
Dr. Lentz is credited with the discovery of post-translational
regulation of pro-inflammatory cytokines in cancer through shedding
of membrane receptors.
This discovery led to the development of the anti-inflammatory
drug Enbrel. He has been awarded numerous international patents
for Methods and Systems to reverse immune tolerance in cancers
and infectious disease.
Over 20 peer reviewed papers were authored by him. He co-authored
two major textbooks and has given numerous international lectures
on the subject of cytokine modulation in advanced cancers and
has been an invited speaker at more than 100 major international
He is currently a senior research scientist of the International
Center for Interdisciplinary Studies of Immunology of Georgetown
University Medical Center, in Washington, D.C., serves as a
Director of the Bavarian Immunology Association GmbH, Director
of the non-profit International Immunology Foundation and is
a consultant to many international biotech companies.
His main clinical interests are extending clinical responses
to maximum disease free intervals obtained by Immunepheresis
and the education of physicians about clinical applications
of tumor immunology.
He continues to support R& D in the field of tumor immunology
to maximize clinical outcomes for the benefit of patients and